Cronos Group/$CRON
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cronos Group
Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.
Ticker
$CRON
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Stayner, Canada
Employees
459
ISIN
CA22717L1013
Website
Cronos Group Metrics
BasicAdvanced
$732M
14.70
$0.13
1.53
-
Price and volume
Market cap
$732M
Beta
1.53
52-week high
$2.54
52-week low
$1.60
Average daily volume
1.6M
Financial strength
Current ratio
27.795
Quick ratio
26.29
Long term debt to equity
0.075
Total debt to equity
0.163
Profitability
EBITDA (TTM)
-34.56
Gross margin (TTM)
31.89%
Net profit margin (TTM)
39.68%
Operating margin (TTM)
-35.23%
Effective tax rate (TTM)
-7.11%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
-2.42%
Return on equity (TTM)
4.59%
Valuation
Price to earnings (TTM)
14.696
Price to revenue (TTM)
5.832
Price to book
0.94
Price to tangible book (TTM)
1.01
Price to free cash flow (TTM)
-105.932
Free cash flow yield (TTM)
-0.94%
Free cash flow per share (TTM)
-1.79%
Growth
Revenue change (TTM)
33.92%
Earnings per share change (TTM)
-186.40%
3-year revenue growth (CAGR)
13.80%
10-year revenue growth (CAGR)
73.23%
3-year earnings per share growth (CAGR)
-45.31%
10-year earnings per share growth (CAGR)
2.43%
What the Analysts think about Cronos Group
Analyst ratings (Buy, Hold, Sell) for Cronos Group stock.
Bulls say / Bears say
Cronos Group's Spinach brand has become the number one cannabis brand in Canada, indicating strong market presence and consumer preference. (markets.businessinsider.com)
The company reported a 38% year-over-year increase in Q3 2024 revenue, showcasing significant growth and operational efficiency. (gurufocus.com)
Cronos Group's strategic option to acquire a stake in U.S. multistate operator PharmaCann positions it favorably for potential expansion into the U.S. market upon federal legalization. (finance.yahoo.com)
Bank of America Securities maintains an 'Underperform' rating for Cronos Group, citing concerns over profitability and market challenges. (markets.businessinsider.com)
The company faces regulatory uncertainties, including unclear U.S. federal cannabis reform and potential changes to the Canadian Cannabis Act, which could negatively impact its valuation. (markets.businessinsider.com)
Cronos Group's profitability remains uncertain, with expectations of achieving positive adjusted EBITDA not anticipated before 2026. (tipranks.com)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
Cronos Group Financial Performance
Revenues and expenses
Cronos Group Earnings Performance
Company profitability
Cronos Group News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cronos Group stock?
Cronos Group (CRON) has a market cap of $732M as of June 30, 2025.
What is the P/E ratio for Cronos Group stock?
The price to earnings (P/E) ratio for Cronos Group (CRON) stock is 14.7 as of June 30, 2025.
Does Cronos Group stock pay dividends?
No, Cronos Group (CRON) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Cronos Group dividend payment date?
Cronos Group (CRON) stock does not pay dividends to its shareholders.
What is the beta indicator for Cronos Group?
Cronos Group (CRON) has a beta rating of 1.53. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.